Resources from the same session
LBA87 - Phase II LITESPARK-003 study of belzutifan in combination with cabozantinib for advanced clear cell renal cell carcinoma (ccRCC)
Presenter: Toni Choueiri
Session: Proffered Paper session 2 - Genitourinary tumours, non-prostate
Resources:
Abstract
Slides
Webcast
LBA88 - Belzutifan versus everolimus in participants (pts) with previously treated advanced clear cell renal cell carcinoma (ccRCC): Randomized open-label phase III LITESPARK-005 study
Presenter: Laurence Albiges
Session: Proffered Paper session 2 - Genitourinary tumours, non-prostate
Resources:
Abstract
Slides
Webcast
1881O - Safety and efficacy of two doses of belzutifan in patients (pts) with advanced RCC: Results of the randomized phase II LITESPARK-013 study
Presenter: Neeraj Agarwal
Session: Proffered Paper session 2 - Genitourinary tumours, non-prostate
Resources:
Abstract
Slides
Webcast
Invited Discussant LBA87, LBA88 and 1881O
Presenter: Lisa Pickering
Session: Proffered Paper session 2 - Genitourinary tumours, non-prostate
Resources:
Slides
Webcast
Q&A
Presenter: All Speakers
Session: Proffered Paper session 2 - Genitourinary tumours, non-prostate
Resources:
Webcast
1882O - RENOTORCH: Toripalimab combined with axitinib versus sunitinib in first-line treatment of advanced renal-cell carcinoma (RCC) - A randomized, open-label, phase III study
Presenter: Xinan Sheng
Session: Proffered Paper session 2 - Genitourinary tumours, non-prostate
Resources:
Abstract
Slides
Webcast
Q&A
Presenter: All Speakers
Session: Proffered Paper session 2 - Genitourinary tumours, non-prostate
Resources:
Webcast